Angeborene Immunität

• 2023 Professor for Medical Immunology at Charité – Universitätsmedizin Berlin and head of Institute of Medical Immunology of the Charité
• 2020 W3 Professor „Immunology of Inflammation” at Charité Medical University and Chair of the Leibniz “Chronic Inflammation” Campus, Berlin
• 2018 Primo Loco W3 in Immunology at the Medical Faculty of the Eberhard Karls Universität Tübingen
• 2017-2020 W2-Heisenberg Professorship at the Charité Medical University, Berlin
• 2009-2017 Group Leader at the Deutsche Rheumaforschungszentrum (DRFZ), Berlin
• 2006 – 2009 PostDoc Charité and DRFZ, Berlin

• 2003 – 2006 PhD at the University of Genova, Italy
• 1998 – 2003 Specialty in Oncology at the National Cancer Institute, Genoa, Italy
• 1991 – 1998 Study of medicine at the University of Florence, Italy

• Board of the German Society of Immunology (DGfI)
• Executive Committee of the European Journal of Immunology (EJI)
• Faculty Member Faculty of 1000 Research
• Committee for the DGFI-Robert Koch Postdoc Prize
• Chief Editor of Frontiers in Immunology – Specialty NK and ILCs (2017-2020)

• 2022 ERC Advanced Grant “MEM-CLONK: Imprinting and clonality of human NK cell memory”
• 2017 DFG-Heisenberg Professorship
• 2016 DFG-nominated member of AcademiaNet – “Expert Database for Outstanding Female Academics
  http://www.academia-net.de/
• 2006 EMBO fellowship

Selection from 2016 ongoing

• 2022-2027 (pending): ERC Advanced Grant “MEM-CLONK: Imprinting and clonality of human NK cell memory”
• 2021 Berlin Health Innovations (BHI) Validation Fund “AntigIn – mRNA-vaccination for the expansion of peptide-specific Natural Killer cells to treat viral infection and cancer”
• 2021-2023 Else Kröner Graduate School for Medical Students “Rethinking Health: Gesundheits- und Präventionsforschung” (Deputy Speaker)
• 2020-2024 Leibniz ScienceCampus Berlin W55/2019 “Comprehensive Center for Chronic Inflammatory Diseases” (Speaker)
• 2020-2023 Leibniz-Kooperative Exzellenz K259/2019 „Identification and modulation of new immune targets in juvenile idiopathic arthritis (JIA)“
• 2019 Berlin Health Innovations (BHI) Validation Fund 2018 “Peptide-based vaccination targeting innate responses against viral infection and cancer”
• 2018 – 2022 DFG-TRR 241 TP B02: “Signals mediating crosstalk of intestinal epithelial cells with innate lymphoid cells in inflammatory bowel diseases”
• 2018 – 2022 DFG-TRR 241 Research Graduate Training (RTG)-Z01
• 2017-2020 DFG-Heisenberg Professorship at the Charité – Universitätsmedizin Berlin
• 2016 – 2022 DFG SSP 1937/1 (RO3565/4-1; 4-2): Innate Lymphoid Cells: “Role of Innate lymphoid cells (ILC) and aryl hydrocarbon receptor (AhR) during pulmonary bacterial infections”

1. Stehle C, Rückert T, Fiancette R, Gajdasik DW, Willis C, Ulbricht C, Durek P, Mashreghi MF, Finke D, Hauser AE, Withers DR, Chang HD, Zimmermann J* and Romagnani C*. T-bet and RORa control lymph node formation by regulating embryonic innate lymphoid cell differentiation. Nat Immunol. 2021 Oct;22(10):1231-1244. doi: 10.1038/s41590-021-01029-6. *equal contribution
2. Hernández DC, Juelke K, Müller NC, Durek P, Ugursu B, Mashreghi MF, Rückert T, Romagnani C. An in vitro platform supports generation of human innate lymphoid cells from CD34+ hematopoietic progenitors that recapitulate ex vivo identity. Immunity. 2021 Oct 12;54(10):2417-2432.e5. doi: 10.1016/j.immuni.2021.07.019.
3. Hammer Q, Rückert T, Borst EM, Dunst J, Haubner A, Durek P, Heinrich F, Gasparoni G, Babic M, Tomic A, Pietra G, Nienen M, Blau IW, Hofmann J, Na IK, Prinz I, Koenecke C, Hemmati P, Babel N, Arnold R, Walter J, Thurley K, Mashreghi MF, Messerle M, Romagnani C. Peptide-specific recognition of human cytomegalovirus strains controls adaptive natural killer cells. Nat Immunol. 2018 May;19(5):453-463. doi: 10.1038/s41590-018-0082-6. Epub 2018 Apr 9.
4. Hammer Q, Rückert T, Romagnani C. Natural killer cell specificity for viral infections. Nat Immunol. 2018 Aug;19(8):800-808. Review.
5. Montaldo E, Teixeira-Alves LG, Glatzer T, Hamann W, Babic M, Paclik D, Stölzel K, Gröne J, Lozza L, Juelke K, Matzmohr N, Loiacono F, Petronelli P, Huntington ND, Moretta L, Mingari MC and Romagnani C. Human RORgt+ CD34+ cells are lineage-specified progenitors of group 3 RORgt+ innate lymphoid cells. Immunity. 2014 Dec 18;41(6):988-1000.